阿尼卡治療公司
DE ˙ DB ˙ US0352551081
€11.90 0.00 (0.00%)
2026-06-04
分享價格
SecurityDE:AKP / Anika Therapeutics, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership309,041 shares
Ownership 2.11%
State Street Corp ownership in AKP / Anika Therapeutics, Inc.

2024-01-22 - State Street Corp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 309,041 shares of Anika Therapeutics, Inc. (DE:AKP). This represents 2.11 percent ownership of the company. In their previous filing dated 2023-02-08 , State Street Corp had reported owning 908,867 shares, indicating a decrease of -66.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-22 2024-01-22 13G/A 908,867 309,041 -66.00 2.11 -66.08
2023-02-08 2023-02-08 13G/A 798,568 908,867 13.81 6.22 12.48
2022-02-10 2022-02-10 13G/A 820,746 798,568 -2.70 5.53 -4.16
2021-02-05 2021-02-05 13G 860,507 820,746 -4.62 5.77 -4.31
2020-02-13 2020-02-13 13G 860,507 6.03

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ANIKA THERAPEUTICS COM 035255108 346,092 9,549 2.84 5,018 55.16 0.0002
2026-02-13 2025-12-31 13F ANIKA THERAPEUTICS COM 035255108 336,543 13,165 4.07 3,234 6.42 0.0001
2025-11-14 2025-09-30 13F ANIKA THERAPEUTICS COM 035255108 323,378 -983 -0.30 3,040 -11.43 0.0001
2025-08-14 2025-06-30 13F ANIKA THERAPEUTICS COM 035255108 324,361 -2,254 -0.69 3,432 -30.11 0.0001
2025-05-15 2025-03-31 13F ANIKA THERAPEUTICS COM 035255108 326,615 12,375 3.94 4,909 -5.09 0.0002
2025-02-14 2024-12-31 13F ANIKA THERAPEUTICS COM 035255108 314,240 9,015 2.95 5,172 -31.40 0.0002
2024-11-14 2024-09-30 13F ANIKA THERAPEUTICS COM 035255108 305,225 -7,667 -2.45 7,539 -4.87 0.0003
2024-08-14 2024-06-30 13F ANIKA THERAPEUTICS COM 035255108 312,892 -2,584 -0.82 7,926 -1.10 0.0003
2024-05-15 2024-03-31 13F ANIKA THERAPEUTICS COM 035255108 315,476 6,435 2.08 8,013 14.44 0.0004
2024-02-14 2023-12-31 13F ANIKA THERAPEUTICS COM 035255108 309,041 -29,630 -8.75 7,003 10.98 0.0003
2023-11-14 2023-09-30 13F ANIKA THERAPEUTICS COM 035255108 338,671 -456,238 -57.39 6,309 -69.45 0.0003
2023-08-14 2023-06-30 13F ANIKA THERAPEUTICS COM 035255108 794,909 -124,879 -13.58 20,652 -21.82 0.0011
2023-05-15 2023-03-31 13F ANIKA THERAPEUTICS COM 035255108 919,788 10,921 1.20 26,416 -1.81 0.0015
2023-05-15 2022-12-31 13F/A-99 ANIKA THERAPEUTICS COM 035255108 908,867 -10,623 -1.16 26,902 22.93 0.0016
2023-05-15 2022-12-31 13F ANIKA THERAPEUTICS COM 035255108 908,867 -10,623 26,902 0.0016
2022-11-15 2022-09-30 13F ANIKA THERAPEUTICS COM 035255108 919,490 51,205 5.90 21,884 12.92 0.0014
2022-08-15 2022-06-30 13F ANIKA THERAPEUTICS COM 035255108 868,285 -61,213 -6.59 19,380 -16.97 0.0012
2022-05-16 2022-03-31 13F ANIKA THERAPEUTICS COM 035255108 929,498 130,930 16.40 23,340 -18.43 0.0012
2022-02-14 2021-12-31 13F ANIKA THERAPEUTICS COM 035255108 798,568 -12,806 -1.58 28,613 -17.14 0.0014
2021-11-15 2021-09-30 13F ANIKA THERAPEUTICS COM 035255108 811,374 -87,021 -9.69 34,532 -11.21 0.0018
2021-08-16 2021-06-30 13F ANIKA THERAPEUTICS COM 035255108 898,395 -42,958 -4.56 38,892 1.29 0.0020
2021-07-09 2021-03-31 13F/A-1 ANIKA THERAPEUTICS COM 035255108 941,353 120,607 14.69 38,398 3.37 0.0022
2021-05-17 2021-03-31 13F ANIKA THERAPEUTICS COM 035255108 941,353 120,607 38,398 0.0022
2021-02-16 2020-12-31 13F ANIKA THERAPEUTICS COM 035255108 820,746 42,553 5.47 37,147 34.88 0.0023
2020-11-10 2020-09-30 13F ANIKA THERAPEUTICS COM 035255108 778,193 -147,291 -15.92 27,540 -21.13 0.0019
2020-08-14 2020-06-30 13F ANIKA THERAPEUTICS COM 035255108 925,484 62,439 7.23 34,919 39.95 0.0025
2020-06-19 2020-03-31 13F/A-1 ANIKA THERAPEUTICS COM 035255108 863,045 2,538 0.29 24,951 -44.08 0.0022
2020-05-11 2020-03-31 13F ANIKA THERAPEUTICS COM 035255108 863,045 2,538 24,951 2,191.2002
2020-02-06 2019-12-31 13F ANIKA THERAPEUTICS COM 035255108 860,507 110,062 14.67 44,617 8.31 0.0031
2019-11-14 2019-09-30 13F ANIKA THERAPEUTICS COM 035255108 750,445 -35,050 -4.46 41,192 29.10 0.0031
2019-08-14 2019-06-30 13F ANIKA THERAPEUTICS COM 035255108 785,495 55,890 7.66 31,907 44.62 0.0024
2019-05-15 2019-03-31 13F ANIKA THERAPEUTICS COM 035255108 729,605 225,518 44.74 22,063 30.23 0.0017
2019-02-12 2018-12-31 13F ANIKA THERAPEUTICS COM 035255108 504,087 -140,703 -21.82 16,942 -37.71 0.0015
2018-11-09 2018-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 644,790 156,228 31.98 27,200 74.00 0.0021
2018-08-14 2018-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 488,562 85,183 21.12 15,632 -22.07 0.0013
2018-05-15 2018-03-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 403,379 24,453 6.45 20,059 -1.81 0.0017
2018-02-14 2017-12-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 378,926 14,599 4.01 20,428 -3.31 0.0016
2017-11-14 2017-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 364,327 -6,106 -1.65 21,127 15.60 0.0018
2017-08-14 2017-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 370,433 21,141 6.05 18,276 20.47 0.0016
2017-05-15 2017-03-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 349,292 32,501 10.26 15,171 -2.17 0.0014
2017-02-09 2016-12-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 316,791 9,917 3.23 15,507 5.59 0.0015
2017-01-13 2016-09-30 13F/A-1 ANIKA THERAPEUTICS Common equity shares 035255108 306,874 13,403 4.57 14,686 -6.74 0.0015
2016-11-14 2016-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 306,874 14,686
2016-08-12 2016-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 293,471 4,755 1.65 15,747 21.96 0.0017
2016-05-20 2016-03-31 13F/A-1 ANIKA THERAPEUTICS Common equity shares 035255108 288,716 -1,875 -0.65 12,912 16.45 0.0014
2016-05-12 2016-03-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 288,716 12,912
2016-02-16 2015-12-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 290,591 -21,350 -6.84 11,088 11.65 0.0012
2015-11-16 2015-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 311,941 -8,626 -2.69 9,931 -6.25 0.0012
2015-08-13 2015-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 320,567 6,744 2.15 10,593 -18.00 0.0011
2015-05-15 2015-03-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 313,823 18,200 6.16 12,919 7.27 0.0013
2015-02-11 2014-12-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 295,623 3,466 1.19 12,044 12.45 0.0012
2014-11-12 2014-09-30 13F/A-1 ANIKA THERAPEUTICS Common equity shares 035255108 292,157 12,096 4.32 10,711 -17.44 0.0012
2014-11-10 2014-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 292,157 10,711
2014-08-12 2014-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 280,061 10,735 3.99 12,974 17.21 0.0014
2014-05-15 2014-03-31 13F/A-1 ANIKA THERAPEUTICS Common equity shares 035255108 269,326 46,169 20.69 11,069 30.02 0.0013
2014-05-13 2014-03-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 269,326 11,069
2014-02-06 2013-12-31 13F/A-1 ANIKA THERAPEUTICS Common equity shares 035255108 223,157 31,585 16.49 8,513 85.51 0.0009
2014-02-06 2013-12-31 13F ANIKA THERAPEUTICS Common equity shares 035255108 175,455 1,745
2013-11-12 2013-09-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 191,572 12,241 6.83 4,589 50.51 0.0006
2013-08-08 2013-06-30 13F ANIKA THERAPEUTICS Common equity shares 035255108 179,331 179,331 3,049 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.